Drug Trial Radar · NCT03176784
UW Quitting Using Intensive Treatment Study (QUITS)
Last checked: Nov 19, 2026Latest source record: Jan 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,251
Actual
Start
Nov 11, 2017
Primary completion
Jul 9, 2020
Study completion Jul 9, 2020
Sponsor
- Lead sponsor
- University of Wisconsin, MadisonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Washington University School of Medicine; National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Jun 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This research will determine whether two highly promising modifications to varenicline treatment (i.e. use of a nicotine patch adjuvant and extended 24-week duration) produce superior smoking outcomes when they are either used together or alone. Despite their promise, the proposed modifications have never been experimentally evaluated relative to standard varenicline pharmacotherapy. Thus, this innovative research will produce novel evidence regarding how best to help smokers quit, and thereby address the leading cause of preventable mortality and morbidity related to cardiovascular and pulmonary diseases.
Conditions
- Tobacco Dependence
Interventions
VareniclineDrug
0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
Nicotine patchDrug
14 mg and 7 mg nicotine patches used. See arms for specific durations.
Placebo PatchOther
Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
Placebo PillOther
Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
Primary outcomes
What the sponsor says the trial is designed to measure.
- 52-Week Point-Prevalence AbstinenceTime frame: Assessed 52 weeks after quit date
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UW Center For Tobacco Research and Intervention
Madison, Wisconsin
UW Center for Tobacco Research and Intervention
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.